This episode details the significant regulatory complexities for Companion Diagnostics (CDx) under the European Union's In Vitro Diagnostic Regulation (IVDR). We explore why these devices are now in a higher risk class, the impact of mandatory consultations with medicinal authorities like the EMA, and the critical need for seamless coordination between IVD manufacturers and their pharmaceutical partners to ensure timely market access.

Key Questions:

- What makes Companion Diagnostics (CDx) a unique challenge under the EU IVDR?

- Why are most CDx considered high-risk Class C devices?

- How does the mandatory consultation with the European Medicines Agency (EMA) impact timelines?

- What are the new clinical evidence requirements for CDx performance evaluation?

- How can IVD manufacturers and pharma partners align their regulatory strategies?

- What happens if the drug and device timelines are not synchronized?

- Why is early-stage coordination crucial for successful market entry?

Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We streamline global market access by combining local expertise in over 30 markets with advanced AI and data tools. Our services cover the entire lifecycle, from regulatory strategy and technical dossier submission to post-market surveillance. By leveraging a single registration process for multiple markets, we help you expand efficiently. Whether you're a startup or a multinational enterprise, our technology-driven solutions ensure compliance and speed. Contact Pure Global at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.